Elevar
1 products tracked · names used in filings: Elevar
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Wed 23 Sep 2026🇺🇸 FDA approval
FDA approves Lyrfigtu (lirafugratinib hydrochloride), a new medicine
Elevar; NDA220425; New molecular entity, Priority review; capsule · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇺🇸 | Lyrfigtu lirafugratinib hydrochloride | Approved | 2026-09-23 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.